Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prenatal serum screening for Down's syndrome].

U Müller1, R Benz, M Krahner-Pilat

  • 1Universitätsfrauenklinik Ulm.

Zeitschrift Fur Geburtshilfe Und Perinatologie
|May 1, 1992
PubMed
Summary

This study assessed Down's syndrome risk non-invasively using maternal serum markers. For women aged 35+, the Dermalog and Alpha programs significantly improved trisomy 21 detection rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Common architecture of Tc toxins from human and insect pathogenic bacteria.

Science advances·2019
Same author

Pore-forming activity of clostridial binary toxins.

Biochimica et biophysica acta·2015
Same author

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.

Cancer chemotherapy and pharmacology·2014
Same author

Reply to Canet et al: Acute kidney injury in critically ill allo-HSCT recipients.

Bone marrow transplantation·2014
Same author

High electric field effects on the cell membranes of Halicystis parvula : A charge pulse study.

Planta·2013
Same author

A new electrical method for the determination of the cell membrane area in plant cells.

Planta·2013

Area of Science:

  • Maternal-fetal medicine
  • Biochemical screening
  • Prenatal diagnostics

Context:

  • Down's syndrome (trisomy 21) is a common chromosomal abnormality.
  • Accurate risk assessment is crucial for informed reproductive decisions.
  • Current screening methods have limitations, particularly in older maternal age groups.

Purpose:

  • To evaluate the efficacy of two commercial analysis programs for non-invasive Down's syndrome risk assessment.
  • To compare test sensitivity and specificity across different maternal age groups.
  • To determine the potential impact of these programs on detection rates and invasive procedure-related risks.

Summary:

  • Maternal serum levels of AFP, free estriol, and beta HCG were analyzed in 619 pregnancies (597 healthy, 22 trisomy 21).
  • Risk was estimated using hormone multiples of the median combined with maternal age.
  • For women aged 35+, the Dermalog program detected 94.4% and Alpha program 88.2% of trisomy 21 cases, with false-positive rates around 19%.

Impact:

  • The study suggests that widespread application of these tests in women over 35 could nearly double Down's syndrome detection rates.
  • Implementing these non-invasive screening tools may reduce the need for amniocentesis, thereby lowering the rate of associated abortions by approximately two-thirds.
  • This research has implications for improving prenatal screening strategies and patient management in high-risk pregnancies.

Related Experiment Videos